Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC and ARX788, our lead product candidate targeting HER2. We have a twenty-year history of establishing collaborations with multiple pharmaceutical companies in additional indications and development projects.

Our team of dedicated professionals is bound by a culture and vision that embraces innovation, practicality, and accountability. Through these shared values, we pursue our mission of bringing next gen ADCs to patients in need of new targeted and stable treatment options. Visit our Careers page for information about joining our team.